Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort

NCT04979780 · clinicaltrials.gov ↗

COMPLETED

Status

3708

Enrollment

INDUSTRY

Sponsor class

Conditions

Treatment of Venous Thromboembolism in Cancer Patients
Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients

Interventions

DRUG: Rivaroxaban (Xarelto, BAY59-7939)
DRUG: Low molecular weight heparin (LMWH)
DRUG: Direct Oral Anticoagulants (DOAC)

Sponsor

Bayer